VITR logo

Vitrolife AB (publ) Stock Price

OM:VITR Community·SEK 12.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

VITR Share Price Performance

SEK 89.90
-109.10 (-54.82%)
SEK 176.75
Fair Value
SEK 89.90
-109.10 (-54.82%)
49.1% undervalued intrinsic discount
SEK 176.75
Fair Value
Price SEK 89.90
AnalystConsensusTarget SEK 176.75
AnalystLowTarget SEK 141.00
AnalystHighTarget SEK 230.00

VITR Community Narratives

AnalystConsensusTarget·
Fair Value SEK 176.75 49.1% undervalued intrinsic discount

Profit Margins And Revenue Outlook Will Support Recovery Trends Ahead

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·
Fair Value SEK 141 36.2% undervalued intrinsic discount

IVF Cycle Recovery And Consumables Momentum Will Support A Fairly Valued Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value SEK 230 60.9% undervalued intrinsic discount

IVF Technology Adoption And Genetic Testing Demand Will Drive Strong Long-Term Upside

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SEK 176.75
49.1% undervalued intrinsic discount
Revenue
6.47% p.a.
Profit Margin
18.21%
Future PE
37.1x
Price in 2029
SEK 207.12
SEK 141
36.2% undervalued intrinsic discount
Revenue
8.42% p.a.
Profit Margin
19.67%
Future PE
25.35x
Price in 2029
SEK 164.57
SEK 230
60.9% undervalued intrinsic discount
Revenue
7.74% p.a.
Profit Margin
21.03%
Future PE
39.44x
Price in 2028
SEK 268.66

Trending Discussion

Updated Narratives

VITR logo

VITR: Restructuring Of Genetic Services Will Drive Future Upside Potential

Fair Value: SEK 176.75 49.1% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VITR logo

IVF Cycle Recovery And Consumables Momentum Will Support A Fairly Valued Outlook

Fair Value: SEK 141 36.2% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VITR logo

IVF Technology Adoption And Genetic Testing Demand Will Drive Strong Long-Term Upside

Fair Value: SEK 230 60.9% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

0 Risks
3 Rewards

Vitrolife AB (publ) Key Details

SEK 3.4b

Revenue

SEK 1.4b

Cost of Revenue

SEK 2.0b

Gross Profit

SEK 7.0b

Other Expenses

-SEK 5.0b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 26, 2026
-37.01
58.05%
-145.70%
18.9%
View Full Analysis

About VITR

Founded
1989
Employees
1151
CEO
Bronwyn Brophy O´Connor
WebsiteView website
www.vitrolife.com

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.

Recent VITR News & Updates

Recent updates

No updates